Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:31:18.519Z.
Consensus retrieved: 2026-10-06T10:27:24.377Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:31:18.519Z.
Quote observation: 2026-10-06T17:29:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a8085c513eceea433d11447c559c3cb4077d09e0e0bb952091b2e74f8d03dae0
Forward PE Ratio (N/A) = Dated Quote Price ($0.32) / Consensus Forward EPS ($-0.21)
FORWARD PE RATIO
N/A
Cosmos Health Inc.
Market Cap
$17.50M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cosmos Health Inc. (COSM) | $17.50M | N/A |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.17M | N/A |
| Lipocine Inc. (LPCN)vs › | $17.15M | N/A |
| Estrella Immunopharma, Inc. (ESLA)vs › | $17.87M | N/A |
| PAVmed Inc. (PAVM)vs › | $17.04M | N/A |
| Palatin Technologies, Inc. (PTN)vs › | $16.76M | N/A |
| Bionano Genomics, Inc. (BNGO)vs › | $16.74M | N/A |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.67M | N/A |
| Dyadic International, Inc. (DYAI)vs › | $16.55M | N/A |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.86M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $0.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.21 | $-0.21 – $-0.21 | 1 | n/m |
| 2027-12-31 | $0.07 | $0.07 – $0.07 | 1 | 4.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
